Drug therapy: Multiple myeloma

被引：1153

作者：

Kyle, RA ^{[1
]}

Rajkumar, SV ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol & Internal Med, Rochester, MN 55905 USA

来源：

关键词：

D O I：

10.1056/NEJMra041875

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1860 / 1873

页数：14

共 125 条

[1] Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma
Abe, M
Hiura, K
Wilde, J
Moriyama, K
Hashimoto, T
Ozaki, S
Wakatsuki, S
Kosaka, M
Kido, S
Inoue, D
Matsumoto, T
[J]. BLOOD, 2002, 100 (06) : 2195 - 2202
[2] Adams J, 1999, CANCER RES, V59, P2615
[3] ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8
[4] VAD-BASED REGIMENS AS PRIMARY-TREATMENT FOR MULTIPLE-MYELOMA
ALEXANIAN, R
BARLOGIE, B
TUCKER, S
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 1990, 33 (02) : 86 - 89
[5] ALEXANIAN R, 1989, EUR J HAEMATOL, V43, P140
[6] ALEXANIAN R, 1992, BLOOD, V80, P887
[7] The proteasome: a novel target for cancer chemotherapy
Almond, JB
Cohen, GM
[J]. LEUKEMIA, 2002, 16 (04) : 433 - 443
[8] Thalidomide and dexamethasone for resistant multiple myeloma
Anagnostopoulos, A
Weber, D
Rankin, K
Delasalle, K
Alexanian, R
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (05) : 768 - 771
[9] Multiple myeloma: How far have we come?
Anderson, KC
[J]. MAYO CLINIC PROCEEDINGS, 2003, 78 (01) : 15 - 17
[10] [Anonymous], 2003, HEMATOL J